Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency

Ajay Bhala, Steven M. Willi, Piero Rinaldo, Michael J. Bennett, Eberhard Schmidt-Sommerfeld, Daniel Hale

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Objective: We identified two additional patients with short-chain acyl-coenzyme A (CoA), further characterized the clinical and biochemical features of this defect, and compared it with other fatty acid oxidation defects. Design: We have measured the in vitro short-chain acyl-coenzyme A dehydrogenase (SCAD) activity in six affected persons with the electron-transfer flavoprotein-linked assay in the presence and absence of anti-medium-chain acyl-CoA dehydrogenase antibody. Urine organic acids, acylglycines, acylcarnitines, and radiolabeled substrate catabolism by skin fibroblasts were also examined. Results: All patients had some neurologic abnormalities, including hypotonia, hypertonia, or seizures. None of the patients had episodes of hypoglycemia; in the only patient tested, fasting ketogenesis was not impaired. Four patients were initially seen in the neonatal period, two with profound metabolic acidosis and two with mild acidemia; the other two cases were recognized in infancy. Enzymatic analysis of cultured skin fibroblasts demonstrated approximately 10% activity of SCAD when compared with control fibroblasts. Gas chromatography and mass spectrometry of urine revealed that ethylmalonic acid was present in all samples but not always at elevated concentrations; methylsuccinic acid and butyrylglycine were sporadically elevated. n-Butyrylcarnitine was often found in urine and plasma. Radiolabeled substrate metabolism was reduced to 40% to 60% of control values. Conclusions: Because affected persons do not consistently excrete characteristic metabolites, the diagnosis of this enzymatic deficiency is difficult. It is necessary to collect and analyze several urine and plasma specimens when the diagnosis is being considered in patients with neurologic abnormalities suggestive of this disorder. (J PEDIATR 1995;126:910-5).

Original languageEnglish (US)
Pages (from-to)910-915
Number of pages6
JournalThe Journal of Pediatrics
Volume126
Issue number6
DOIs
StatePublished - Jan 1 1995

Fingerprint

Acyl-CoA Dehydrogenase
Urine
Nervous System Malformations
Fibroblasts
Electron-Transferring Flavoproteins
Acyl Coenzyme A
Skin
Muscle Hypotonia
Acidosis
Hypoglycemia
Gas Chromatography-Mass Spectrometry
Short chain Acyl CoA dehydrogenase deficiency
Fasting
Seizures
Fatty Acids
Acids
Antibodies

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Bhala, Ajay ; Willi, Steven M. ; Rinaldo, Piero ; Bennett, Michael J. ; Schmidt-Sommerfeld, Eberhard ; Hale, Daniel. / Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency. In: The Journal of Pediatrics. 1995 ; Vol. 126, No. 6. pp. 910-915.
@article{2da911a23adc476bab13e559a0e9ef90,
title = "Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency",
abstract = "Objective: We identified two additional patients with short-chain acyl-coenzyme A (CoA), further characterized the clinical and biochemical features of this defect, and compared it with other fatty acid oxidation defects. Design: We have measured the in vitro short-chain acyl-coenzyme A dehydrogenase (SCAD) activity in six affected persons with the electron-transfer flavoprotein-linked assay in the presence and absence of anti-medium-chain acyl-CoA dehydrogenase antibody. Urine organic acids, acylglycines, acylcarnitines, and radiolabeled substrate catabolism by skin fibroblasts were also examined. Results: All patients had some neurologic abnormalities, including hypotonia, hypertonia, or seizures. None of the patients had episodes of hypoglycemia; in the only patient tested, fasting ketogenesis was not impaired. Four patients were initially seen in the neonatal period, two with profound metabolic acidosis and two with mild acidemia; the other two cases were recognized in infancy. Enzymatic analysis of cultured skin fibroblasts demonstrated approximately 10{\%} activity of SCAD when compared with control fibroblasts. Gas chromatography and mass spectrometry of urine revealed that ethylmalonic acid was present in all samples but not always at elevated concentrations; methylsuccinic acid and butyrylglycine were sporadically elevated. n-Butyrylcarnitine was often found in urine and plasma. Radiolabeled substrate metabolism was reduced to 40{\%} to 60{\%} of control values. Conclusions: Because affected persons do not consistently excrete characteristic metabolites, the diagnosis of this enzymatic deficiency is difficult. It is necessary to collect and analyze several urine and plasma specimens when the diagnosis is being considered in patients with neurologic abnormalities suggestive of this disorder. (J PEDIATR 1995;126:910-5).",
author = "Ajay Bhala and Willi, {Steven M.} and Piero Rinaldo and Bennett, {Michael J.} and Eberhard Schmidt-Sommerfeld and Daniel Hale",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/S0022-3476(95)70207-5",
language = "English (US)",
volume = "126",
pages = "910--915",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "6",

}

Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency. / Bhala, Ajay; Willi, Steven M.; Rinaldo, Piero; Bennett, Michael J.; Schmidt-Sommerfeld, Eberhard; Hale, Daniel.

In: The Journal of Pediatrics, Vol. 126, No. 6, 01.01.1995, p. 910-915.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency

AU - Bhala, Ajay

AU - Willi, Steven M.

AU - Rinaldo, Piero

AU - Bennett, Michael J.

AU - Schmidt-Sommerfeld, Eberhard

AU - Hale, Daniel

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Objective: We identified two additional patients with short-chain acyl-coenzyme A (CoA), further characterized the clinical and biochemical features of this defect, and compared it with other fatty acid oxidation defects. Design: We have measured the in vitro short-chain acyl-coenzyme A dehydrogenase (SCAD) activity in six affected persons with the electron-transfer flavoprotein-linked assay in the presence and absence of anti-medium-chain acyl-CoA dehydrogenase antibody. Urine organic acids, acylglycines, acylcarnitines, and radiolabeled substrate catabolism by skin fibroblasts were also examined. Results: All patients had some neurologic abnormalities, including hypotonia, hypertonia, or seizures. None of the patients had episodes of hypoglycemia; in the only patient tested, fasting ketogenesis was not impaired. Four patients were initially seen in the neonatal period, two with profound metabolic acidosis and two with mild acidemia; the other two cases were recognized in infancy. Enzymatic analysis of cultured skin fibroblasts demonstrated approximately 10% activity of SCAD when compared with control fibroblasts. Gas chromatography and mass spectrometry of urine revealed that ethylmalonic acid was present in all samples but not always at elevated concentrations; methylsuccinic acid and butyrylglycine were sporadically elevated. n-Butyrylcarnitine was often found in urine and plasma. Radiolabeled substrate metabolism was reduced to 40% to 60% of control values. Conclusions: Because affected persons do not consistently excrete characteristic metabolites, the diagnosis of this enzymatic deficiency is difficult. It is necessary to collect and analyze several urine and plasma specimens when the diagnosis is being considered in patients with neurologic abnormalities suggestive of this disorder. (J PEDIATR 1995;126:910-5).

AB - Objective: We identified two additional patients with short-chain acyl-coenzyme A (CoA), further characterized the clinical and biochemical features of this defect, and compared it with other fatty acid oxidation defects. Design: We have measured the in vitro short-chain acyl-coenzyme A dehydrogenase (SCAD) activity in six affected persons with the electron-transfer flavoprotein-linked assay in the presence and absence of anti-medium-chain acyl-CoA dehydrogenase antibody. Urine organic acids, acylglycines, acylcarnitines, and radiolabeled substrate catabolism by skin fibroblasts were also examined. Results: All patients had some neurologic abnormalities, including hypotonia, hypertonia, or seizures. None of the patients had episodes of hypoglycemia; in the only patient tested, fasting ketogenesis was not impaired. Four patients were initially seen in the neonatal period, two with profound metabolic acidosis and two with mild acidemia; the other two cases were recognized in infancy. Enzymatic analysis of cultured skin fibroblasts demonstrated approximately 10% activity of SCAD when compared with control fibroblasts. Gas chromatography and mass spectrometry of urine revealed that ethylmalonic acid was present in all samples but not always at elevated concentrations; methylsuccinic acid and butyrylglycine were sporadically elevated. n-Butyrylcarnitine was often found in urine and plasma. Radiolabeled substrate metabolism was reduced to 40% to 60% of control values. Conclusions: Because affected persons do not consistently excrete characteristic metabolites, the diagnosis of this enzymatic deficiency is difficult. It is necessary to collect and analyze several urine and plasma specimens when the diagnosis is being considered in patients with neurologic abnormalities suggestive of this disorder. (J PEDIATR 1995;126:910-5).

UR - http://www.scopus.com/inward/record.url?scp=0029060330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029060330&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(95)70207-5

DO - 10.1016/S0022-3476(95)70207-5

M3 - Article

C2 - 7776094

AN - SCOPUS:0029060330

VL - 126

SP - 910

EP - 915

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 6

ER -